Drug
MLN 8237 clinical trials
Also written MLN8237 and Alisertib.
- studies test it
- 60
- open now
- 4
- in phase 3
- 1
- first study started
- 2007
Keep track of what changes. Save the MLN 8237 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Development codes
- MLN8237
- 63
Other names
Studies by the year they started
60 studies that test it; most in 2013 (13)
| Year | Studies |
|---|---|
| 2007 | 2 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 3 |
| 2012 | 8 |
| 2013 | 13 |
| 2014 | 5 |
| 2015 | 9 |
| 2016 | 3 |
| 2019 | 1 |
| 2020 | 2 |
| 2024 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 39
- Phase 2
- 25
- Phase 3
- 1
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 25 · Other 35
Millennium Pharmaceuticals, Inc. (21) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (4) · Puma Biotechnology, Inc. (3) · Sidney Kimmel Cancer Center at Thomas Jefferson University (2) · Children's Oncology Group (2) · Massachusetts General Hospital (2) · Mayo Clinic (2)
Often tested with
Tested in the same studies.
Sapanisertib (4) · Paclitaxel (4) · Irinotecan (3) · Bortezomib (2) · Rituximab (2) · Cetuximab (2) · Osimertinib (1) · Pembrolizumab (1)
Studies
Open first, then newest update. How each study uses MLN 8237 is read from its arms, and is right about nine times in ten.
Testing it · 60
- A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06369285Written as Alisertib
- A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)RecruitingPhase 2Puma Biotechnology, Inc.NCT07465757Written as Alisertib
- Targeting Aurora A Kinase to Overcome Treatment Resistance in Advanced HR+/HER2+ Breast CancerNot yet recruitingPhase 2University of Wisconsin, MadisonNCT07706179Written as Alisertib
- A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerRecruitingPhase 2Puma Biotechnology, Inc.NCT06095505Written as Alisertib
- Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin LymphomaActive, not recruitingPhase 1National Cancer Institute (NCI)NCT01695941Written as Alisertib
- Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung CancerCompletedPhase 1Collin BlakelyNCT04085315Written as Alisertib
- Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT04479306Written as Alisertib
- Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerCompletedPhase 1/2M.D. Anderson Cancer CenterNCT04555837Written as Alisertib
- Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate CancerCompletedPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01848067Written as Alisertib
- Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade GliomasCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT02186509Written as Alisertib
- Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast CancerCompletedPhase 2US Oncology ResearchNCT02187991Written as Alisertib
- Phase II Trial of Alisertib (MLN8237) in Salvage Malignant MesotheliomaCompletedPhase 2M.D. Anderson Cancer CenterNCT02293005Written as Alisertib
- Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic CancerCompletedPhase 1Edward KimNCT01924260Written as alisertib
- Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast CancerCompletedPhase 1University of Colorado, DenverNCT02719691Written as Alisertib
- MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal CarcinomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT00853307Written as Alisertib
- Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic LeukemiaStatus unknownNot applicableNorthwestern UniversityNCT02530619Written as Alisertib
- Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or LeukemiaCompletedPhase 2Children's Oncology GroupNCT01154816Written as Alisertib
- Phase II Trial of Alisertib With Induction Chemotherapy in High-risk AMLCompletedPhase 2Massachusetts General HospitalNCT02560025Written as Alisertib
- A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic MalignanciesCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02327169Written as Alisertib
- A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory LymphomaCompletedPhase 1Millennium Pharmaceuticals, Inc.NCT02259010Written as Alisertib
See all 60 studies that test MLN 8237 →
Given in every arm · 4 — MLN 8237 is usual care beside what is tested
- Alisertib With or Without Fulvestrant in Treating Patients With Locally Advanced or Metastatic, Endocrine-Resistant Breast CancerCompletedPhase 2Mayo ClinicNCT02860000Written as Alisertib
- Phase 2 Study of Alisertib Therapy for Rhabdoid TumorsActive, not recruitingPhase 2St. Jude Children's Research HospitalNCT02114229Written as alisertib
- MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal AdenocarcinomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02551055Written as Alisertib
- MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- VincristineCompletedPhase 1/2Millennium Pharmaceuticals, Inc.NCT01397825Written as Alisertib (MLN8237)